Galien week of innovation


OCT. 23-27

Galien Medal
PHARMA - Tuesday Oct. 24


12 PM - 1 PM ET I Lung, Gland, Soft Tissue, Blood and Skin Cancers

Assessing the current state of scientific progress in understanding the basic evolution of cancer as well as nominee experience in moving promising drug targets into clinical trials, regulatory approvals and market acceptance.


Robert Consalvo Sr
Dr Strategic Com Engagement, H1


Blueprint Medicines - GAVRETO® (pralsetinib)

Epizyme Inc. - TAZVERIK®

Joshua Bauml

Joshua Bauml, MD
Global Medical Head - Amivantamab NSCLC Program, The Janssen Pharmaceutical Companies of Johnson & Johnson

Patrice A. Lee, PhD

Patrice A. Lee, PhD
Vice President, Pharmacology, Toxicology and Exploratory Development, Pfizer, Inc.


Susan Pandya
Head of Cancer Metabolism Global Development Oncology & Immuno-Oncology, Servier Pharmaceuticals

1 PM - 2 PM ET I Central Nervous System (CNS) Disorders

CNS drugs often take longer to develop and have lower success rates than other types of drug candidates. What strategies are nominees developing to “de-risk” novel CNS therapies and speed the pathway to clinical and market success?

Hugh Marston

Hugh Marston, PhD
Senior Vice President & Global Head CNS Disease Research, Boehringer Ingelheim


Alkermes, Inc. - LYBALVI®

Machelle - RELYVRIO - GWI spokesperson

Machelle Manuel
Vice President, Head Global Medical Affairs, Amylyx Pharmaceuticals, Inc.

Nilesh Mehta _Genentech-roche-1

Nilesh Mehta
Global Franchise Head, Ophthalmology, Genentech, a Member of the Roche Group


Lewis Warrington
Chief Medical Officer, Ironshore Therapeutics


2 PM - 3 PM ET I Infectious Diseases and Reproductive Health

With a global pandemic raising awareness of the importance of vaccines and anti-viral medicines, are private-sector R&D incentives aligned to meet growing market needs? Gauging unmet needs in women’s health therapeutics and promising new trends in research.

Jessica Federer

Jessica Federer
Board Member Sage Therapeutics

Jared - Sunlenca - GWI spokesperson

Jared Baeten
Vice President, HIV Clinical Development,
Gilead Sciences, Inc.


3 PM - 4 PM ET I Autoimmune, Metabolic and Genetic Diseases

Given the complex biological and genetic interrelationships that characterize autoimmune, metabolic and aged-based genetic disorders, how has research science progressed in ensuring patients with these conditions can benefit from a more personalized approach to treatment?

Michael Ringel,  PhD

Michael Ringel, JD, PhD
Managing Director & Senior Partner, BCG


Aurinia Pharmaceuticals Inc. - LUPKYNIS

Mirum Pharmaceuticals, Inc. - LIVMARLI

Michael Vincent

Michael Vincent, MD, PhD
Senior Vice President, Chief Scientific Officer, Inflammation & Immunology,

Paulo Fontoura

Paulo Fontoura
SVP and Global Head of Neuroscience and I2O, Genentech, a Member of the Roche Group

Francisco Leon - Sanofi

Francisco Leon
Chief Scientific Officer & Co-Founder, Provention Bio, A Sanofi Company